4,6-dimethyl-7-hydroxy-1-indanone | 84174-65-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4,6-dimethyl-7-hydroxy-1-indanone
• 英文别名: 2,3-dihydro-4,6-dimethyl-7-hydroxy-1H-inden-1-one；7-hydroxy-4,6-dimethyl-2,3-dihydroinden-1-one
• CAS: 84174-65-2
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: NHMFOWVPDZOLFP-UHFFFAOYSA-N

物化性质

• 熔点：
  117-119 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  357.1±42.0 °C(Predicted)
• 密度：
  1.206±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,6-dimethyl-7-hydroxy-1-indanone 在 钯 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 反应 5.0h， 生成 2-benzyl-4,6-dimethyl-7-hydroxy-1-indanone
  参考文献：
  名称：

  具有中枢神经系统刺激活性的新型脑保护剂。2.1-（酰基氨基）-7-羟基茚满衍生物的合成和药理作用。

  摘要：

  在不断寻找具有中枢神经系统（CNS）刺激活性的新型脑保护药物时，已合成了一系列1-（酰基氨基）-7-羟基茚满衍生物，并对其双重活性进行了测试。根据其对低氧条件下（210 mmHg）小鼠存活的影响，评估了该系列化合物的脑保护活性，并通过评估其对脑震荡引起的昏迷恢复的促进作用，检查了其对中枢神经系统的刺激活性。在小鼠中。几种化合物以30 mg / kg po的剂量延长了低氧条件下小鼠的存活率。该系列中的四种化合物在相同剂量下均表现出CNS刺激作用。其中，7-羟基-1-[[4-（3-甲氧基苯基）-1-哌嗪基]乙酰基]氨基] -2,2,4,6-四甲基茚满（18，OPC-14117），

  DOI：

  10.1021/jm00111a014
• 作为产物：
  描述：

  2,4-二甲基苯酚 在 4-二甲氨基吡啶 、 aluminum (III) chloride 、 potassium chloride 、 苯甲酰氯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 生成 4,6-dimethyl-7-hydroxy-1-indanone
  参考文献：
  名称：

  高活性受限氯化铝配合物将二氧化碳环加成到环氧化物

  摘要：

  二氧化碳 (CO 2 ) 和环氧化物向环状碳酸酯的转化由于其低成本、丰度、低毒性和可再生性而受到广泛关注。因此，基于用于环氧化物/CO 2偶联反应的双（水杨亚胺）配体开发了新型受限氯化铝配合物。与芳环相连的五元环旨在扩大铝中心周围的配位袋，如单晶 X 射线晶体学所示。将环氧丙烷 (PO) 添加到氯化铝络合物和四丁基溴化铵 (TBAB) 的混合物中，迅速得到（配体）Al-OCH(Me)CH 2 Cl 和（配体）Al-OCH(Me)CH 2Br 等量。发现（配体）Al-Cl 和 TBAB 之间的阴离子交换比 PO 的开环更快。从一系列催化剂筛选和优化来看，芳环上没有取代基的催化剂2g和TBAB的组合对于PO/CO 2偶联反应显示出非常高的活性（TOF高达10 800 h -1）。该催化剂体系扩展到十一个以上的环氧化物实例。此外，对于末端环氧化物和内部环氧化物，都观察到了生产环状碳酸酯的优异选择性。

  DOI：

  10.1039/d1dt01903a

文献信息

• Indane derivatives and salts thereof
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04792628A1

  公开（公告）日：1988-12-20

  Indane derivatives and their salts represented by the general formula (1), ##STR1## wherein R.sup.1 is an amino group which may have lower alkyl groups as the substituents, a hydroxylimino group, an alkanoylamino group having 1 to 10 carbon atoms which may have halogen atoms as the substituents, a lower alkylsulfonylamino group, a phenylsulfonylamino group which may have lower alkyl groups as the substituents on the phenyl ring, a benzoylamino group having lower alkyl groups as the substituents on the phenyl ring, and a phenyl-lower alkylamino group having a hydroxyl groups or a lower alkyl groups as the substituents on the phenyl ring, R.sup.2 is a hydrogen atom, a lower alkyl group, a halogen atom, a nitro group, an amino group, an amino-lower alkyl group, a lower alkanoylamino group, a lower alkanoylamino-lower alkyl group which may have halogen atoms as the substituents, a lower alkylthio group, a 1-piperidinesulfonyl group, or a lower alkenyl group; R.sup.3 is a hydrogen atom, a lower alkyl group, or a halogen atom; R.sup.4 and R.sup.5 are the same or different from each other, and are each a hydrogen atom, or a lower alkyl group; provided that when R.sup.1 is a hydroxylimino group, then R.sup.2 and R.sup.3 should not be hydrogen atoms at the same time. The indane derivatives and their salts are useful as preventive and curative agents for various diseases and disorders caused by the excessive formation and accumulation of the active oxygen radicals and the peroxidized substances in the living body, and/or the defects of phylaxis mechanisms of the living body, for example anti-arreriosclerotic agents, carcinogenesis preventive agents, carcinostatic agents, anti-inflammatory agents, analgesics, autoimmune disease curative agents, platelets aggregation inhibitory agents, hypotensive agents, anti-hyperlipemic agents, retinosis of immature infant and cataract preventive and curative agents. The indane derivatives and their salts are also useful as antioxidants for oils and fats being contained in processed foods.

  Indane衍生物及其盐用通式（1）表示，其中R.sup.1是氨基团，可能具有较低的烷基基团作为取代基，羟基亚胺基团，具有1至10个碳原子的烷酰胺基团，可能具有卤素原子作为取代基，较低的烷基磺酰胺基团，苯基磺酰胺基团，可能具有苯环上的较低烷基基团作为取代基，苯基烷酰胺基团，在苯环上具有较低烷基基团作为取代基，以及苯基较低烷基氨基基团，在苯环上具有羟基或较低烷基基团作为取代基，R.sup.2是氢原子，较低烷基基团，卤素原子，硝基基团，氨基团，氨基较低烷基基团，较低烷酰胺基团，可能具有卤素原子作为取代基，较低烷基硫基团，1-哌啶磺酰基团或较低烯基基团；R.sup.3是氢原子，较低烷基基团或卤素原子；R.sup.4和R.sup.5相同或不同，均为氢原子或较低烷基基团；但是当R.sup.1是羟基亚胺基团时，R.sup.2和R.sup.3不能同时为氢原子。Indane衍生物及其盐可用作预防和治疗各种疾病和障碍的药物，这些疾病和障碍是由于活性氧自由基和过氧化物在生体内的过度形成和积累以及生体免疫机制的缺陷而引起的，例如抗动脉粥样硬化药物，癌症预防剂，抗癌剂，抗炎剂，止痛剂，自身免疫疾病治疗剂，血小板聚集抑制剂，降压剂，降血脂剂，未成熟婴儿视网膜病和白内障预防和治疗剂。Indane衍生物及其盐也可用作加工食品中含有的油脂的抗氧化剂。
• SYNERGISTIC FUNGICIDAL AND ALGICIDAL COMPOSITIONS INCLUDING 7-HYDROXY-INDANONE BENZOYLHYDRAZONES AND COPPER
  申请人：Siddall Thomas L.

  公开号：US20120045522A1

  公开（公告）日：2012-02-23

  The present invention relates to the use of mixtures containing 7-hydroxy-indanone benzoylhydrazone compounds and copper for controlling the growth of fungi and algae.

  本发明涉及使用含有7-羟基茚酮苯甲酰腙化合物和铜的混合物来控制真菌和藻类的生长。
• 2,3-dihydro-1H-indene derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05242919A1

  公开（公告）日：1993-09-07

  Novel 2,3-dihydro-1H-indene derivatives and salts thereof represented by the general formula (1), ##STR1## [wherein R.sup.1 and R.sup.2 are each a hydrogen atom, a lower alkyl group, a phenyl group which may have halogen atoms and/or alkyl groups as the substituents on the phenyl ring; R.sup.3 is a halgoen atom or a lower alkyl group; R.sup.4 is a hydrogen atom, a halogen atom, a phenyl-lower alkyl group, a cycloalkyl-lower alkyl group or the like; R.sup.5 is a hydroxyimino group, an alkylamino group or a group of the formula --NHR.sup.8 (wherein R.sup.8 is a hydrogen atom, a halogen-substituted lower alkanoyl group or the like); R.sup.6 is a hydrogen atom or a phenyl group; and R.sup.7 is a hydrogen atom or a lower alkyl group]. The 2,3-dihydro-1H-indene derivatives and salt thereof are useful as improving agents for treating anoxemic and hypoxic symptoms and syndromes accompanied therewith, cerebral activators, amnesia curvative agents, presbyophrenia curvative agents, treating agents for breathing arrest and improving agents for hypoxia accompanied with potassium cyanide poisoning, as well as useful an anti-inflammatory agents and hypotensive agents.

  一种由通式（1）表示的新颖的2,3-二氢-1H-茚衍生物及其盐，其中：##STR1## [其中R.sup.1和R.sup.2均为氢原子，较低的烷基，苯基，其苯环上可能有卤原子和/或烷基作为取代基；R.sup.3为卤原子或较低的烷基；R.sup.4为氢原子，卤原子，苯基-较低烷基，环烷基-较低烷基或类似物；R.sup.5为羟肟基，烷基氨基或公式--NHR.sup.8的基团（其中R.sup.8为氢原子，卤代较低脂肪酰基或类似物）；R.sup.6为氢原子或苯基；R.sup.7为氢原子或较低的烷基]。2,3-二氢-1H-茚衍生物及其盐可作为改善治疗缺氧和低氧症状和综合症的剂量，脑活化剂，改善失忆症的剂量，老年痴呆症的治疗剂量，呼吸停止的治疗剂量和改善氰化钾中毒伴随的低氧症的剂量，以及有用的抗炎剂和降压剂。
• 1-amino-2,3-dihydro-1H-indene compounds
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04788130A1

  公开（公告）日：1988-11-29

  Novel 2,3-dihydro-1H-indene derivatives and salts thereof represented by the general formula (1), ##STR1## [wherein R.sup.1 and R.sup.2 are each a hydrogen atom, a lower alkyl group, a phenyl group which may have halogen atoms and/or alkyl groups as the substituents on the phenyl ring; R.sup.3 is a halogen atom or a lower alkyl group; R.sup.4 is a hydrogen atom, a halogen atom, a phenyl-lower alkyl group, a cycloalkyl-lower alkyl group or the like; R.sup.5 is a hydroxyimino group, an alkylamino group or a group of the formula --NHR.sup.8 (wherein R.sup.8 is a hydrogen atom, a halogen-substituted lower alkanoyl group or the like); R.sup.6 is a hydrogen atom or a phenyl group; and R.sup.7 is a hydrogen atom or a lower alkyl group]. The 2,3-dihydro-1H-indene derivatives and salt thereof are useful as improving agents for treating anoxemic and hypoxic symptoms and syndromes accompanied therewith, cerebral activators, amnesia curative agents, presbyophrenia curative agents, treating agents for breathing arrest and improving agents for hypoxia accompanied with potassium cyanide poisoning, as well as useful as anti-inflammatory agents and hypotensive agents.

  通式（1）所表示的新型2,3-二氢-1H-茚衍生物及其盐，其中R1和R2分别是氢原子、较低的烷基、苯基，苯环上可能带有卤原子和/或烷基取代基；R3是卤原子或较低的烷基；R4是氢原子、卤原子、苯基-较低烷基、环烷-较低烷基或类似基团；R5是羟亚胺基、烷基氨基或式--NHR8的基团（其中R8是氢原子、卤代较低酰基或类似基团）；R6是氢原子或苯基；R7是氢原子或较低的烷基。这些2,3-二氢-1H-茚衍生物及其盐可用作改善缺氧和低氧症状和伴随症候群的治疗剂、脑活化剂、改善失忆症的药剂、老年痴呆症的治疗剂、呼吸停止的治疗剂和改善伴随钾氰化物中毒的低氧症的药剂，以及作为抗炎剂和降压剂。
• 2,3-dihydro-1H-indene derivatives and their use as pharmaceutical agents
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US05055474A1

  公开（公告）日：1991-10-08

  Novel 2,3-dihydro-1H-indene derivatives and salts thereof represented by the general formula (1), ##STR1## [wherein R.sup.1 and R.sup.2 are each a hydrogen atom, a lower alkyl group, a phenyl group which may have halogen atoms and/or alkyl groups as the substituents on the phenyl ring; R.sup.3 is a halogen atom or a lower alkyl group; R.sup.4 is a hydrogen atom, a halogen atom, a phenyl-lower alkyl group, a cycloalkyl-lower alkyl group or the like; R.sup.5 is a hydroxyimino group, an alkylamino group or a group of the formula --NHR.sup.8 (wherein R.sup.8 is a hydrogen atom, a halogen-substituted lower alkanoyl group or the like); R.sup.6 is a hydrogen atom or a phenyl group; and R.sup.7 is a hydrogen atom or a lower alkyl group]. The 2,3-dihydro-1H-indene derivatives and salt thereof are useful as improving agents for treating anoxemic and hypoxic symptoms and syndromes accompanied therewith, cerebral activators, amnesia curative agents, presbyophrenia curative agents, treating agents for breathing arrest and improving agents for hypoxia accompanied with potassium cyanide poisoning, as well as useful as anti-inflammatory agents and hypotensive agents.

  通式（1）所表示的新型2,3-二氢-1H-茚衍生物及其盐，其中R1和R2分别是氢原子、低碳基、苯基，苯环上可能有卤素基团和/或烷基基团作为取代基；R3是卤素原子或低碳基；R4是氢原子、卤素原子、苯基-低碳基、环烷基-低碳基或类似物；R5是羟肟基、烷基氨基或公式--NHR8的基团（其中R8是氢原子、卤素取代的低碳酰基基团或类似物）；R6是氢原子或苯基；R7是氢原子或低碳基。这些2,3-二氢-1H-茚衍生物及其盐可作为改善缺氧和低氧症状和综合征的治疗剂、脑活化剂、改善记忆障碍的治疗剂、老年痴呆症的治疗剂、呼吸骤停的治疗剂和改善氰化钾中毒引起的低氧症状的治疗剂，以及作为抗炎剂和降压剂使用。